R&S Pharmchem is the main supplier of MANNAC (N-Acetyl-D-Mannosamine) in the world.
Assay : 98% Min(HPLC)
CAS No.: 7772-94-3
Description: N-Acetyl-D-mannosamine is a ubiquitous but rare monosaccharide involved in a range of metabolic processes.It is a constituent of neuraminic acids, glycolipids and glycoproteins.
Application : N-Acetyl-D-mannosamine is used for the synthesis of sialic acid(N-acetylneuraminic). It is also a synthetic intermediate for a number of carbohydrate-derived families of biologically active compounds and pharmaceutical candidates.
Packaging : N-Acetylmannonsamine is sealed in two polyethylene liners and packed in 20 kg fibre drums. Customer specific packaging can be provided.
N-acetylmannosamine is usually called ManNAc in Glycolyscience line.
People can synthesize N-acetylneuraiminic acid through N-acetylmannosamine. Also ManNAc can be used to prepare for the further sugar derivation,which can be used in human medicine and nutrition products. The most important product is N-Acetylmannosamine-6-phosphate(ManNAc-6-p).
1. N-acetyl-D-mannosamine analogues as potential inhibitors of sialic acid biosynthesis, for detail information click here!
The 1,3,6-tri-O-acetyl and 1,3,6-tri-O-acetyl-4-O-mesyl analogues of N-acetyl-D-mannosamine and the corresponding N-trifluoroacetyl derivative have been synthesized, and their effects on the proliferation of Friend erythroleukemia cells in culture have been evaluated. The acetamido series showed a dependency on the 4-substituent for optimum cytotoxicity while the trifluoroacetamido series did not. Thus, the 1,3,4,6-tetra-O-acetyl and 1,3,6-tri-O-acetyl-4-O-mesyl analogues of N-acetyl-D-mannosamine were 10-fold and 42-fold more active, respectively, than 2-acetamido-1,3,6-tri-O-acetyl-2-deoxy-alpha-D-mannopyranose as inhibitors of cellular replication. The corresponding trifluoroacetamido analogues were essentially equiactive and had a potency equivalent to that of the 4-O-mesyl derivative in the acetamido series.
2. ¦Á-N-Acetylmannosamine (ManNAc) Synthesis via Rhodium(II)-Catalyzed Oxidative Cyclization of Glucal 3-Carbamates, for detail information click here!
Glucal 3-carbamates 1 and 7 underwent oxidative cyclization with iodobenzene diacetate or iodosobenzene in the presence of Rh2(OAc)4, providing mannosamine 2-N,3-O-oxazolidinones. With iodosobenzene, incorporation of 4-penten-1-ol provided a readily separable anomeric mixture of n-pentenyl glycosides, with the anomers exhibiting pronounced differences in reactivity as glycosyl donors. N-acylation of the sugar oxazolidinones led to -selective glycosyl donors for the elaboration of various 2-mannosamine frameworks. Alternatively, the anomeric n-pentenyl glycosides of N-Cbz 2-mannosamine oxazolidinones were converted separately to oxazolidinone-opened derivatives 28 and 28. These served as stereoconvergent glycosyl donors, and the -linked products were readily advanced to a variety of N-acetylmannosamine (ManNAc) frameworks, using an intramolecular ON acetyl transfer as the final step.
3. Establishment of N-Acetylmannosamine (ManNAc) Analogue-Resistant Cell Lines as Improved Hosts for Sialic Acid Engineering Applications, for detail information click here!
Metabolic substrate-based sialic acid engineering techniques, where exogenously supplied N-acetylmannosamine (ManNAc) analogues are utilized by the sialic acid biosynthetic pathway, allow the cell surface to be endowed with novel physical and chemical properties and show promise for increasing the quality of recombinant glycoproteins. The in vitro toxicity of many ManNAc analogues, however, hinders the large-scale adoption of this technology. In this study, we used a selection strategy where cells were subjected to progressively higher levels of ManNAc analogues to establish novel cell lines that showed decreased sensitivity to analogue-induced in vitro toxicity. The decreased sensitivity to sugar analogue-induced apoptosis, demonstrated by the Annexin V-FITC detection method and DNA fragmentation assays, corresponded to increased sialic acid production in the resistant cell lines. The ManNAc analogue-resistant cell lines exhibited cross-resistance to apoptosis induced by staurosporine and an apoptosis-activating Fas antibody. We propose that the selection strategy employed to develop these novel cell lines, which serve as superior hosts for substrate-based sialic acid engineering applications, will generally apply to the development of host cell lines for biotechnology applications.